Pulmonary Fibrosis News and Research RSS Feed - Pulmonary Fibrosis News and Research

VUMC receives $11 million renewal grant to advance pulmonary fibrosis research

VUMC receives $11 million renewal grant to advance pulmonary fibrosis research

Vanderbilt University Medical Center has received an $11 million program project renewal grant from the National Heart, Lung and Blood Institute to study the genetics and underlying biological mechanisms that lead to idiopathic pulmonary fibrosis (IPF). [More]
New disease gene linked to shortened telomeres appears to raise risk of pulmonary fibrosis-emphysema

New disease gene linked to shortened telomeres appears to raise risk of pulmonary fibrosis-emphysema

Johns Hopkins researchers say they have identified a new disease gene that, when mutated, appears to increase the risk in a small number of people of developing emphysema and a lung-scarring condition known as pulmonary fibrosis. [More]
Scientists use Regeneration Intelligence to assess perturbation status of many signaling pathways

Scientists use Regeneration Intelligence to assess perturbation status of many signaling pathways

Insilico Medicine, Inc in collaboration with scientists from Atlas Regeneration, Inc, Vision Genomics, Inc and Howard University published two research papers on fibrosis in the lung and liver and fibrotic signatures in glaucoma. [More]
Testing lung health online: an interview with Professor Stephen Holgate

Testing lung health online: an interview with Professor Stephen Holgate

In our latest report – The Battle for Breath – the impact of lung disease in the UK, figures suggest that 1 in 5 (around 12.7 million) have been diagnosed with a lung condition in the UK. If you’re over the age of 70, this rises to 1 in 3. [More]
Male hormones can reverse biological drivers of aging, study shows

Male hormones can reverse biological drivers of aging, study shows

Telomerase, an enzyme naturally found in the human organism, is the closest of all known substances to a "cellular elixir of youth." In a recent study, Brazilian and US researchers show that sex hormones can stimulate production of this enzyme. [More]
Advances in inhaled drug delivery: an interview with Dr Robert Clarke

Advances in inhaled drug delivery: an interview with Dr Robert Clarke

Delivering drugs to the lungs via inhalation has a number of potential advantages over traditional routes of administration like pills or injections. For treating pulmonary diseases, the obvious logic we are applying is topical delivery to the airways via inhalation. [More]
New Rutgers research aims at exploring gender differences in lung cancer

New Rutgers research aims at exploring gender differences in lung cancer

Lung cancer is the leading cause of cancer death in both men and women. Lung cancer diagnoses have more than doubled among females in the past 38 years, while having fallen 29 percent among males, according to the American Lung Association. [More]
Wresting back control of CHI3L1 protein could stave off cancer spread in mice

Wresting back control of CHI3L1 protein could stave off cancer spread in mice

For cancer to spread, the cells that take off into the bloodstream must find a tissue that will permit them to thrive. They don't just go looking, though. Instead, they actively prepare the tissue, in one case by co-opting a protein that suppresses defenses the body would otherwise mount. [More]
Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

New analyses presented at the American Thoracic Society’s 2016 annual conference (ATS 2016) further add to the efficacy and safety profile of OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF). [More]
3-D imaging of fibroblastic foci may help researchers study disease progression in IPF patients

3-D imaging of fibroblastic foci may help researchers study disease progression in IPF patients

Idiopathic pulmonary fibrosis (IPF) is a fatal disease in which progressive scarring of the lungs leads to respiratory failure. Lung scarring in IPF takes the form of aggregates of proliferating fibroblasts and myofibroblasts, known as "fibroblastic foci", which deposit collagen and other fibrotic components. These foci are thought to form in response to lung injury. [More]
M10 peptide could help protect systemic sclerosis patients against fibrotic damage

M10 peptide could help protect systemic sclerosis patients against fibrotic damage

The results of preclinical studies by investigators at the Medical University of South Carolina (MUSC) reported in the April 2016 issue of Translational Research suggest that the M10 peptide could help protect against fibrotic damage in patients with systemic sclerosis, particularly in those who develop interstitial lung diseases (ILD), its deadliest complication. [More]
Complete genetic map of scleroderma opens door for diagnosis and targeted treatment

Complete genetic map of scleroderma opens door for diagnosis and targeted treatment

Scleroderma is an autoimmune disease that affects one out of every 10,000 people in Europe and North America, mostly middle-aged women, and causes death in a high percentage of cases. [More]
Understanding idiopathic pulmonary fibrosis: an interview with Michael Durheim, M.D.

Understanding idiopathic pulmonary fibrosis: an interview with Michael Durheim, M.D.

IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65. [More]
VolitionRx's NuQ blood test accurately detects 86% of subjects with Idiopathic Pulmonary Fibrosis

VolitionRx's NuQ blood test accurately detects 86% of subjects with Idiopathic Pulmonary Fibrosis

VolitionRx Limited today announced preliminary data from a pilot study demonstrating that the Company’s NuQ® blood test detected 86% of subjects with a deadly lung disease, called Idiopathic Pulmonary Fibrosis (IPF). [More]
Systemic sclerosis: an interview with Dr Kristin Highland

Systemic sclerosis: an interview with Dr Kristin Highland

Systemic sclerosis, also known as scleroderma, is a rare disease characterized by the thickening and scarring of connective tissue of multiple organs in the body [More]
New international survey provides insights into emotional truths of living with IPF

New international survey provides insights into emotional truths of living with IPF

An international survey of over 500 people living with idiopathic pulmonary fibrosis (IPF) in more than 20 countries worldwide reveals the real-life emotions faced by those with the devastating disease. [More]
Rare Disease Day 2016: Boehringer Ingelheim launches new initiatives to raise awareness of IPF

Rare Disease Day 2016: Boehringer Ingelheim launches new initiatives to raise awareness of IPF

Boehringer Ingelheim, working with pharmaphorum media, has brought together patients, patient groups and globally renowned clinicians to launch a report into IPF entitled Inspiration - a new initiative dedicated to raising awareness of IPF,1 a rare disease that is relatively unheard of, frequently misdiagnosed and little understood. [More]
UA College of Pharmacy assistant professor developing dry powder inhalers to treat pulmonary diseases

UA College of Pharmacy assistant professor developing dry powder inhalers to treat pulmonary diseases

Heidi M. Mansour, PhD, assistant professor in the University of Arizona College of Pharmacy, is working to develop advanced dry powder inhalers to treat and prevent pulmonary diseases. [More]
Apellis Pharmaceuticals completes $47.1M Series D preferred stock financing

Apellis Pharmaceuticals completes $47.1M Series D preferred stock financing

Apellis Pharmaceuticals, Inc., today announced that it has completed a $47.1 million Series D preferred stock financing, co-led by new investors Cormorant Asset Management, Hillhouse Capital Group and venBio Global Strategic Fund, joining existing investors Morningside Venture Investments, AJU IB Investment, and Epidarex Capital. [More]
Antiscarring paste can halt fibrosis caused by radiation treatment

Antiscarring paste can halt fibrosis caused by radiation treatment

An antiscarring paste when applied to the skin of mice halts fibrosis caused by the radiation used in cancer therapy. That is according to a study led by researchers at Laura and Isaac Perlmutter Cancer Center to be published tomorrow in the January edition of the Journal of the Federation of American Societies for Experimental Biology, or FASEB. [More]
Advertisement
Advertisement